Spexis: Funding, Investors & Team (Sep 2026)
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
Spexis has raised $3.0M across 2 funding rounds on record, the most recent an undisclosed round of $2.5M announced in Aug 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Spexis Company Profile and Key Stats
Latest funding round on record: Aug 2023.
Spexis Funding Rounds
Spexis raised $500k in an undisclosed round announced in Feb 2023.
6 months later, an undisclosed round of $2.5M was announced in Aug 2023.
Spexis Founders and Leadership Team
No contact details are on record for this team yet.
Spexis Funding Compared to Other Biotechnology Startups
Spexis' latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Spexis in Biotechnology and Allschwil
Companies Similar to Spexis
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Spexis Funding FAQs
What does Spexis do?
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
How much funding has Spexis raised?
Spexis has raised $3.0M across 2 rounds on record. The most recent is an undisclosed round of $2.5M announced in Aug 2023.
When did Spexis last raise funding?
Spexis' most recent funding round on record is an undisclosed round of $2.5M, announced in Aug 2023.
Who is the CEO of Spexis?
Jean Pierre Obrecht is listed as CEO at Spexis.
Where is Spexis headquartered?
Spexis is based in Allschwil, Basel-Landschaft, Switzerland.
How many employees does Spexis have?
Spexis is in the 11-50 employee band.
How does Spexis' funding compare to other Biotechnology startups?
Spexis' latest round of $2.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Spexis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Spexis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.